Brief: Pulmatrix Announces Positive Top Line Results From Phase 1 Study With PUR3100

Pulmatrix

04/01/2023 14:06

Jan 4 (Reuters) - Pulmatrix Inc  PULM.O :
    * PULMATRIX ANNOUNCES POSITIVE TOP LINE RESULTS FROM A PHASE
1
STUDY WITH PUR3100, A NOVEL ORALLY INHALED DIHYDROERGOTAMINE
(DHE), FOR ACUTE MIGRAINE
    * PULMATRIX INC - PUR3100 WAS SAFE AND ALL DOSES HAD FEWER
GI SIDE
EFFECTS COMPARED TO IV DHE
    * PULMATRIX INC - PUR3100 DEMONSTRATED A FIVE-MINUTE TMAX
AND CMAX
WITHIN TARGETED THERAPEUTIC RANGE FOR ALL THREE DOSES TESTED
    * PULMATRIX INC - DOSE SELECTION IS UNDERWAY FOR PHASE 2
STUDY AND
AN FDA MEETING WILL BE REQUESTED THIS MONTH

Source text for Eikon:  ID:nPn1jTKhja 
Further company coverage:  PULM.O 
 ((Reuters.Briefs@thomsonreuters.com;))